Houston study aims to catch liver cancer early with simple tests
NCT ID NCT04785534
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is screening 1,000 patients at the HOPE clinic in Houston for liver fibrosis and cirrhosis using surveys, blood tests, and a non-invasive liver scan called FibroScan. The goal is to find early signs of liver damage that could lead to cancer, so that prevention or early treatment can be started. Participants are existing or new clinic patients aged 18 and older.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify people at high risk for liver cancer earlier, potentially improving survival through early detection.
- What could go wrong
- This is an observational screening study, not a treatment trial. It may not directly prevent cancer or change outcomes for participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER AND INTRAHEPATIC BILE DUCT CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.